Author Topic: (LACTRIMS) MS mortality in Mexico, 1998-2012  (Read 63 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9664
  • MS diagnosed 1980
  • Location: Pacific Northwest
(LACTRIMS) MS mortality in Mexico, 1998-2012
« on: November 18, 2016, 12:09:44 pm »
LACTRIMS (the Latin American Committee for Treatment and Research in Multiple Sclerosis) is convening in Buenos Aires, November 15-19, 2016. Below is an abstract of a paper presented there.

Multiple sclerosis mortality in Mexico: An analysis of death certificates of the nation (1998–2012)

Erwin Chiquete1, Irene Treviño-Frenk1 and José de Jesús Flores-Rivera2
1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; 2Instituto de Neurología y Neurocirugía, La Habana, Cuba


 Multiple sclerosis (MS) is a growing health problem in countries [experiencing an] economical and epidemiological transition to technological development. In Latin America, information on the health burden of MS is scarce.


To describe the contribution of MS as a cause of death during the period 1998–2012 in Mexico.


Information provided by the National Health Information System (SINAIS, SSA Mexico) was extracted from the yearly electronic databases on the causes of death. A combined electronic database was arranged from the 15-year period for direct analysis. Cases of MS as the main cause of death were identified by means of the International Classification of Diseases 10th version (ICD-10, WHO) coding system (code G35). [What is presented here is] the crude number of deaths attributed to MS and the annual mortality rate.


The primary data source consisted of 7,563,143 death certificates in the study period. In 1998, 444,629 deaths were registered, which increased to 602,272 in 2012, coinciding with the general population growth (96 million inhabitants in 1998, 110 million in 2012). The number of MS deaths rose since 1998 (113 deaths) through 2012 (279 deaths). The crude mortality rate also showed a significant ascending pattern from 1998 (0.12 per 100,000 inhabitants) to 2012 (0.25 per 100,000 inhabitants) (trend, p).


This analysis is the first in Latin America showing that MS significantly reduces life expectancy, as compared with the rest of the population. The population mortality rate attributed to MS in Mexico is growing, possibly due to diagnosis bias, technological availability, and the evolution of diagnostic criteria. Nonetheless, a true increase in the incidence of MS cannot be ruled out.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
4 Replies
Last post April 11, 2017, 07:11:54 pm
by agate
0 Replies
Last post July 09, 2017, 02:07:47 pm
by agate
0 Replies
Last post November 06, 2018, 04:22:41 pm
by agate
0 Replies
Last post September 16, 2020, 10:12:55 pm
by agate
0 Replies
Last post January 30, 2022, 03:44:29 pm
by agate